313 related articles for article (PubMed ID: 36356599)
1. Non-viral precision T cell receptor replacement for personalized cell therapy.
Foy SP; Jacoby K; Bota DA; Hunter T; Pan Z; Stawiski E; Ma Y; Lu W; Peng S; Wang CL; Yuen B; Dalmas O; Heeringa K; Sennino B; Conroy A; Bethune MT; Mende I; White W; Kukreja M; Gunturu S; Humphrey E; Hussaini A; An D; Litterman AJ; Quach BB; Ng AHC; Lu Y; Smith C; Campbell KM; Anaya D; Skrdlant L; Huang EY; Mendoza V; Mathur J; Dengler L; Purandare B; Moot R; Yi MC; Funke R; Sibley A; Stallings-Schmitt T; Oh DY; Chmielowski B; Abedi M; Yuan Y; Sosman JA; Lee SM; Schoenfeld AJ; Baltimore D; Heath JR; Franzusoff A; Ribas A; Rao AV; Mandl SJ
Nature; 2023 Mar; 615(7953):687-696. PubMed ID: 36356599
[TBL] [Abstract][Full Text] [Related]
2. Neoantigen-targeted CD8
Puig-Saus C; Sennino B; Peng S; Wang CL; Pan Z; Yuen B; Purandare B; An D; Quach BB; Nguyen D; Xia H; Jilani S; Shao K; McHugh C; Greer J; Peabody P; Nayak S; Hoover J; Said S; Jacoby K; Dalmas O; Foy SP; Conroy A; Yi MC; Shieh C; Lu W; Heeringa K; Ma Y; Chizari S; Pilling MJ; Ting M; Tunuguntla R; Sandoval S; Moot R; Hunter T; Zhao S; Saco JD; Perez-Garcilazo I; Medina E; Vega-Crespo A; Baselga-Carretero I; Abril-Rodriguez G; Cherry G; Wong DJ; Hundal J; Chmielowski B; Speiser DE; Bethune MT; Bao XR; Gros A; Griffith OL; Griffith M; Heath JR; Franzusoff A; Mandl SJ; Ribas A
Nature; 2023 Mar; 615(7953):697-704. PubMed ID: 36890230
[TBL] [Abstract][Full Text] [Related]
3. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
4. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers.
Lowery FJ; Krishna S; Yossef R; Parikh NB; Chatani PD; Zacharakis N; Parkhurst MR; Levin N; Sindiri S; Sachs A; Hitscherich KJ; Yu Z; Vale NR; Lu YC; Zheng Z; Jia L; Gartner JJ; Hill VK; Copeland AR; Nah SK; Masi RV; Gasmi B; Kivitz S; Paria BC; Florentin M; Kim SP; Hanada KI; Li YF; Ngo LT; Ray S; Shindorf ML; Levi ST; Shepherd R; Toy C; Parikh AY; Prickett TD; Kelly MC; Beyer R; Goff SL; Yang JC; Robbins PF; Rosenberg SA
Science; 2022 Feb; 375(6583):877-884. PubMed ID: 35113651
[TBL] [Abstract][Full Text] [Related]
5. Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function.
Schober K; Müller TR; Gökmen F; Grassmann S; Effenberger M; Poltorak M; Stemberger C; Schumann K; Roth TL; Marson A; Busch DH
Nat Biomed Eng; 2019 Dec; 3(12):974-984. PubMed ID: 31182835
[TBL] [Abstract][Full Text] [Related]
6. Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.
Rath JA; Arber C
Cells; 2020 Jun; 9(6):. PubMed ID: 32570906
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous Deletion of Endogenous TCRαβ for TCR Gene Therapy Creates an Improved and Safe Cellular Therapeutic.
Morton LT; Reijmers RM; Wouters AK; Kweekel C; Remst DFG; Pothast CR; Falkenburg JHF; Heemskerk MHM
Mol Ther; 2020 Jan; 28(1):64-74. PubMed ID: 31636040
[TBL] [Abstract][Full Text] [Related]
8. Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons.
Zhao Q; Jiang Y; Xiang S; Kaboli PJ; Shen J; Zhao Y; Wu X; Du F; Li M; Cho CH; Li J; Wen Q; Liu T; Yi T; Xiao Z
Front Immunol; 2021; 12():658753. PubMed ID: 33859650
[TBL] [Abstract][Full Text] [Related]
9. CRISPR-engineered T cells in patients with refractory cancer.
Stadtmauer EA; Fraietta JA; Davis MM; Cohen AD; Weber KL; Lancaster E; Mangan PA; Kulikovskaya I; Gupta M; Chen F; Tian L; Gonzalez VE; Xu J; Jung IY; Melenhorst JJ; Plesa G; Shea J; Matlawski T; Cervini A; Gaymon AL; Desjardins S; Lamontagne A; Salas-Mckee J; Fesnak A; Siegel DL; Levine BL; Jadlowsky JK; Young RM; Chew A; Hwang WT; Hexner EO; Carreno BM; Nobles CL; Bushman FD; Parker KR; Qi Y; Satpathy AT; Chang HY; Zhao Y; Lacey SF; June CH
Science; 2020 Feb; 367(6481):. PubMed ID: 32029687
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells.
Legut M; Dolton G; Mian AA; Ottmann OG; Sewell AK
Blood; 2018 Jan; 131(3):311-322. PubMed ID: 29122757
[TBL] [Abstract][Full Text] [Related]
11. Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer.
Matsuda T; Leisegang M; Park JH; Ren L; Kato T; Ikeda Y; Harada M; Kiyotani K; Lengyel E; Fleming GF; Nakamura Y
Clin Cancer Res; 2018 Nov; 24(21):5357-5367. PubMed ID: 29720506
[No Abstract] [Full Text] [Related]
12. Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.
Tsuji T; Yoneda A; Matsuzaki J; Miliotto A; Ryan C; Koya RC; Odunsi K
Cancer Immunol Res; 2018 May; 6(5):594-604. PubMed ID: 29588318
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9-medaited knockout of endogenous T-cell receptor in Jurkat cells and generation of NY-ESO-1-specific T cells: An in vitro study.
Safarzadeh Kozani P; Shokrgozar MA; Evazalipour M; Roudkenar MH
Int Immunopharmacol; 2022 Sep; 110():109055. PubMed ID: 35853277
[TBL] [Abstract][Full Text] [Related]
14. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.
Rupp LJ; Schumann K; Roybal KT; Gate RE; Ye CJ; Lim WA; Marson A
Sci Rep; 2017 Apr; 7(1):737. PubMed ID: 28389661
[TBL] [Abstract][Full Text] [Related]
16. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance.
Chandran SS; Klebanoff CA
Immunol Rev; 2019 Jul; 290(1):127-147. PubMed ID: 31355495
[TBL] [Abstract][Full Text] [Related]
17. A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens.
Hu Z; Anandappa AJ; Sun J; Kim J; Leet DE; Bozym DJ; Chen C; Williams L; Shukla SA; Zhang W; Tabbaa D; Steelman S; Olive O; Livak KJ; Kishi H; Muraguchi A; Guleria I; Stevens J; Lane WJ; Burkhardt UE; Fritsch EF; Neuberg D; Ott PA; Keskin DB; Hacohen N; Wu CJ
Blood; 2018 Nov; 132(18):1911-1921. PubMed ID: 30150207
[TBL] [Abstract][Full Text] [Related]
18. High-throughput identification of antigen-specific TCRs by TCR gene capture.
Linnemann C; Heemskerk B; Kvistborg P; Kluin RJ; Bolotin DA; Chen X; Bresser K; Nieuwland M; Schotte R; Michels S; Gomez-Eerland R; Jahn L; Hombrink P; Legrand N; Shu CJ; Mamedov IZ; Velds A; Blank CU; Haanen JB; Turchaninova MA; Kerkhoven RM; Spits H; Hadrup SR; Heemskerk MH; Blankenstein T; Chudakov DM; Bendle GM; Schumacher TN
Nat Med; 2013 Nov; 19(11):1534-41. PubMed ID: 24121928
[TBL] [Abstract][Full Text] [Related]
19. Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for Cancer.
Fix SM; Jazaeri AA; Hwu P
Cancer Discov; 2021 Mar; 11(3):560-574. PubMed ID: 33563662
[TBL] [Abstract][Full Text] [Related]
20. Needle in a Haystack: The Naïve Repertoire as a Source of T Cell Receptors for Adoptive Therapy with Engineered T Cells.
D'Ippolito E; Wagner KI; Busch DH
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33171940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
